Non-alcoholic fatty liver disease (NAFLD) is an important risk factor for type 2 diabetes and cardiovascular diseases. In a Perspective in Cell Metabolism, the researchers first highlight the dysregulation of hepatokines – proteins released from the liver – in people with NAFLD. Then, they discuss pathomechanisms of type 2 diabetes and cardiovascular diseases specifically related to NAFLD by focusing on hepatokine-related organ crosstalk. Finally, they propose how the determination of major hepatokines and adipokines (proteins released from fat) can be used for the identification of subtypes of people with NAFLD, to better implement precision medicine in clinical practice.
Worldwide more than 25% of adults and 3-10% of children have NAFLD. The percentage of NAFLD is much higher when obesity and/or diabetes is present in adults (60%) and in children (⁓40%). These numbers are alarming, because NAFLD, and more so non-alcoholic steatohepatitis, is the main cause of chronic liver disease and liver cancer. Furthermore, results from large studies reveal that NAFLD associates with ⁓2.5-fold increased risk of type 2 diabetes and ⁓1.5-fold increased risk of cardiovascular events. But what are the mechanisms by which the fatty liver impacts on the genesis of type 2 diabetes and cardiovascular diseases? Furthermore, how can the impact of fatty liver be separated from the impact of increased abdominal obesity, which is often found in people with fatty liver, on these diseases?
The researchers have been studying these questions since many years. They have identified important hepatokines that are dysregulated in NAFLD and have described their role in metabolism.
‘We found that the hepatokine fetuin-A is increasingly produced by the fatty liver and that it strongly predicts the incidence of type 2 diabetes and cardiovascular events. We also identified mechanisms of cellular action of fetuin-A to promote insulin resistance, subclinical inflammation and impairment of insulin secretion’, highlights the author and adds: ‘We identified another important hepatokine which is increasingly produced by the fatty liver – follistatin. We found mechanisms up-regulating the production of follistatin in the liver and identified the mechanisms by which follistatin increases glucose levels and insulin resistance. In large human cohorts we found that follistatin associates with an increased risk of type 2 diabetes’.
In their present article the researchers describe the mechanisms of action of these hepatokines and summarize knowledge about other hepatokines that are being studied in the scientific community.
Finally, the researchers made use of a currently very popular research tool – cluster analysis, a data dimensionality reduction approach – to disentangle the close relationship between fatty liver and abdominal obesity and to identify subtypes of people with fatty liver.
Clustering the parameters liver fat content, visceral fat mass, the hepatokine fetuin-A and the adipokine adiponectin, they identified 3 clusters. The clusters 1 and 3 had similar insulin resistance and elevated liver fat content but largely differed in the plasma levels of fetuin-A and adiponectin.
The researchers concluded that they identified subtypes of people with fatty liver having different pathomechanisms of insulin resistance and that the research into hepatokines may be helpful to find other subtypes of fatty liver in the future.
https://www.cell.com/cell-metabolism/fulltext/S1550-4131(23)00006-2
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fthe-role-of-hepatokines&filter=22
The role of hepatokines in NAFLD
- 805 views
- Added
Latest News
Defective myelin promotes A…
By newseditor
Posted 09 Jun
NAD+ metabolic enzyme's rol…
By newseditor
Posted 09 Jun
Viruses such as SARS-CoV-2…
By newseditor
Posted 09 Jun
A pair of brain regions pro…
By newseditor
Posted 09 Jun
How the gut microbiome resp…
By newseditor
Posted 08 Jun
Other Top Stories
The metastatic spread of breast cancer accelerates during sleep
Read more
Breast duct immunotoxin treatment for early breast cancer
Read more
Targeting cancer-associated fibroblasts to treat esophageal cancer
Read more
How tumors make immune cells promote cancer growth
Read more
Activation of a glycolytic enzyme in the metastasis of pancreatic c…
Read more
Protocols
Hardwiring tissue-specific…
By newseditor
Posted 08 Jun
Using mass spectrometry ima…
By newseditor
Posted 07 Jun
Low-threshold, high-resolut…
By newseditor
Posted 05 Jun
Optical opening of the bloo…
By newseditor
Posted 04 Jun
Protocol to establish a gen…
By newseditor
Posted 03 Jun
Publications
Myelin dysfunction drives a…
By newseditor
Posted 09 Jun
Steroid receptor coactivato…
By newseditor
Posted 09 Jun
Taurine linked with healthy…
By newseditor
Posted 09 Jun
SARS-CoV-2 infection and vi…
By newseditor
Posted 09 Jun
Cancer-cell-derived fumarat…
By newseditor
Posted 09 Jun
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 10 Mar
ASCO-2020-GYNECOLOGIC CANCER
By newseditor
Posted 10 Mar